New imaging tracers could transform how doctors detect and treat breast cancer
Researchers are advancing diagnostic tools that could do double duty: finding breast cancers earlier while simultaneously delivering targeted therapy. The approach, detailed in a new review of modern radiotracers, promises to reduce treatment guesswork and potentially improve patient outcomes—a development that could reshape oncology practice and the economics of cancer care.
Originaltitel: Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications
<p>BackgroundExpanding therapeutic possibilities have improved disease-related prospects for breast cancer patients. Pathological analysis on a tumor biopsy is the current reference standard biomarker used to select for treatment with targeted anticancer drugs. This method has, however, several limitations, related to intra- and intertumoral as well as spatial heterogeneity in receptor expression as well as the need to perform invasive procedures that are not always technically feasible.Main bodyIn this narrative review, we focus on the current role of molecular imaging with contemporary radiotracers for positron emission tomography (PET) in breast cancer. We provide an overview of diagnostic radiotracers that represent treatment targets, such as programmed death ligand 1, human epidermal growth factor receptor 2, polyadenosine diphosphate-ribose polymerase and estrogen receptor, and discuss developments in therapeutic radionuclides for breast cancer management.ConclusionImaging of treatment targets with PET tracers may provide a more reliable precision medicine tool to find the right treatment for the right patient at the right time. In addition to visualization of the target of treatment, theranostic trials with alpha- or beta-emitting isotopes provide a future treatment option for patients with metastatic breast cancer.</p>